Abstract: Dexibuprofen, the active enantiomer of ibuprofen, acts faster and causes less stress on the body compared to ibuprofen. It effectively relieves acute somatic and visceral pain. Thus, it meets the guideline criteria: good evidence, high safety profile and patient acceptance with minimized side effects.